Contract Research Organizations (CROs) play a pivotal role in pharmacovigilance by providing specialized services in adverse drug reaction (ADR) monitoring, case processing, signal detection, safety database management, and regulatory reporting. For B.Pharm students, understanding how CROs support clinical trials and post-marketing surveillance, ensure compliance with ICH and national regulations, prepare aggregate reports (PBRER/PSUR/DSUR), and implement risk management plans is essential. CROs often perform literature screening, expedited 15-day SUSAR reporting, aggregate analyses, and safety audits while maintaining data quality, SOPs, and client oversight. This topic bridges pharmacology, regulatory affairs, and safety science. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What is the primary role of a CRO in pharmacovigilance?
- Designing marketing strategies for drugs
- Managing pharmacovigilance activities on behalf of sponsors
- Conducting only non-clinical laboratory tests
- Issuing marketing authorizations
Correct Answer: Managing pharmacovigilance activities on behalf of sponsors
Q2. Which document contains the minimum elements required for an Individual Case Safety Report (ICSR)?
- Marketing Authorization Application
- ICH E2B (ICSR) specification
- Clinical Study Protocol
- Good Laboratory Practice (GLP) guidance
Correct Answer: ICH E2B (ICSR) specification
Q3. In many regulatory frameworks, what is the usual reporting timeline for a non-life-threatening SUSAR?
- 24 hours
- 7 calendar days
- 15 calendar days
- 90 days
Correct Answer: 15 calendar days
Q4. Which coding dictionary is standard for coding adverse event terms in pharmacovigilance?
- ICD-10
- SNOMED CT
- MedDRA
- LOINC
Correct Answer: MedDRA
Q5. What is the first step in signal management performed by CRO pharmacovigilance teams?
- Regulatory submission
- Signal detection
- Risk minimization implementation
- Clinical trial design
Correct Answer: Signal detection
Q6. What does PBRER stand for?
- Periodic Benefit-Risk Evaluation Report
- Product Batch Release Evaluation Report
- Post-marketing Biologic Risk Evaluation Report
- Pharmacovigilance Basic Regulatory Evaluation Report
Correct Answer: Periodic Benefit-Risk Evaluation Report
Q7. Which regulation or guidance specifies electronic transmission standards for ICSRs (e.g., E2B(R3))?
- ICH E2B(R3)
- ICH Q10
- FDA 21 CFR Part 11 only
- GCP E6(R2)
Correct Answer: ICH E2B(R3)
Q8. Which causality assessment method is commonly used by regulatory pharmacovigilance teams worldwide?
- WHO-UMC causality categories
- Body Mass Index (BMI) calculation
- CAPA matrix
- GCP checklist
Correct Answer: WHO-UMC causality categories
Q9. How does an Adverse Drug Reaction (ADR) differ from an Adverse Event (AE)?
- ADR requires evidence of causal relationship with the drug, AE is any untoward medical occurrence
- AE is always expected; ADR is always unexpected
- AE refers only to laboratory abnormalities
- ADR is reported only in clinical trials
Correct Answer: ADR requires evidence of causal relationship with the drug, AE is any untoward medical occurrence
Q10. Which activity is typically performed by CROs during case processing?
- Marketing authorization approval
- ICSR intake, triage, data entry, medical review and coding
- Manufacturing of investigational products
- Hospital patient care
Correct Answer: ICSR intake, triage, data entry, medical review and coding
Q11. Who retains the ultimate legal responsibility for pharmacovigilance even when a CRO is contracted?
- The Contract Research Organization (CRO)
- The local hospital only
- The Sponsor (marketing authorization holder)
- The clinical investigator
Correct Answer: The Sponsor (marketing authorization holder)
Q12. Which of the following is an essential element of a Pharmacovigilance Agreement (PVA) between sponsor and CRO?
- Marketing budget allocation
- Detailed roles, responsibilities, timelines and data ownership for PV tasks
- Laboratory assay SOPs only
- Clinical study randomization code
Correct Answer: Detailed roles, responsibilities, timelines and data ownership for PV tasks
Q13. Which aggregate safety report is specifically prepared during clinical development to summarize safety data across studies?
- PSUR
- PBRER
- DSUR
- Periodic Benefit-Risk Update (PBRU)
Correct Answer: DSUR
Q14. What is a common KPI used by CRO pharmacovigilance teams to measure performance?
- Number of marketing campaigns completed
- Case processing turnaround time (TAT) for ICSRs
- Quantity of drug manufactured
- Number of clinical sites visited for recruitment
Correct Answer: Case processing turnaround time (TAT) for ICSRs
Q15. Which global database collects adverse reaction reports across the European Economic Area?
- FAERS
- VigiBase
- EudraVigilance
- MedWatch
Correct Answer: EudraVigilance
Q16. What is the role of literature screening in CRO pharmacovigilance?
- Identify published safety information that may generate ICSRs or signals
- Replace spontaneous reporting systems
- Perform chemical analysis of active substances
- Manage clinical trial enrollment
Correct Answer: Identify published safety information that may generate ICSRs or signals
Q17. Which of the following is a key component of a Risk Management Plan (RMP)?
- Manufacturing site locations
- Safety specification, pharmacovigilance plan and risk minimization measures
- Investigator payment schedules
- Marketing strategies for adverse events
Correct Answer: Safety specification, pharmacovigilance plan and risk minimization measures
Q18. Which international organization maintains VigiBase, a global database of individual case safety reports?
- Food and Agriculture Organization (FAO)
- World Health Organization (WHO) Uppsala Monitoring Centre
- European Medicines Agency (EMA)
- International Council for Harmonisation (ICH)
Correct Answer: World Health Organization (WHO) Uppsala Monitoring Centre
Q19. What is the primary advantage of using ICH E2B(R3) for ICSR transmission?
- Faster clinical trial enrollment
- Standardized structured electronic exchange of case data
- Improved drug solubility
- Automatic causality assessment
Correct Answer: Standardized structured electronic exchange of case data
Q20. Which activity ensures the quality and compliance of CRO pharmacovigilance operations?
- PV audits and inspections with CAPA tracking
- Only annual marketing reports
- Clinical site patient recruitment
- Manufacturing batch release testing
Correct Answer: PV audits and inspections with CAPA tracking
Q21. Which system is commonly used by regulators to receive safety reports from marketing authorization holders in the USA?
- EudraVigilance
- VigiBase
- FAERS (FDA Adverse Event Reporting System)
- CIOMS database
Correct Answer: FAERS (FDA Adverse Event Reporting System)
Q22. During case triage, which factor is most important to determine immediate reporting obligations?
- Patient’s insurance status
- Seriousness and expectedness of the event
- Geographic location of the reporter
- Drug price
Correct Answer: Seriousness and expectedness of the event
Q23. What is one responsibility of CROs regarding data privacy in pharmacovigilance?
- Publish patient identifiers in public reports
- Ensure processing of personal data complies with applicable laws such as GDPR
- Share raw patient medical records without consent
- Ignore data transfer agreements
Correct Answer: Ensure processing of personal data complies with applicable laws such as GDPR
Q24. Which report summarizes global safety information periodically after marketing authorization?
- DSUR
- Investigator Brochure
- PBRER/PSUR
- Clinical Study Report
Correct Answer: PBRER/PSUR
Q25. Who typically performs causality assessment for individual cases in a CRO pharmacovigilance team?
- Medical reviewers or qualified pharmacovigilance physicians
- Graphic designers
- Clinical trial participants
- Manufacturing technicians
Correct Answer: Medical reviewers or qualified pharmacovigilance physicians
Q26. Which statistical technique is often used in signal detection to identify disproportionate reporting?
- Disproportionality analysis (e.g., PRR, ROR, IC)
- ANOVA for clinical endpoints
- Kaplan-Meier survival analysis
- HPLC assay validation
Correct Answer: Disproportionality analysis (e.g., PRR, ROR, IC)
Q27. What is included in CRO responsibilities for post-marketing surveillance?
- Maintaining safety database, literature monitoring, signal detection, and periodic reporting
- Only manufacturing of dosage forms
- Hiring clinical investigators for all trials
- Granting marketing authorizations
Correct Answer: Maintaining safety database, literature monitoring, signal detection, and periodic reporting
Q28. Which document outlines investigator responsibilities including SAE reporting during clinical trials?
- Investigator Brochure and Clinical Study Protocol
- PBRER exclusively
- Marketing Authorization Letter
- MedDRA browser manual
Correct Answer: Investigator Brochure and Clinical Study Protocol
Q29. What is a common output of a CRO signal evaluation activity?
- Signal validation report with recommended regulatory actions or further investigation
- New drug pricing model
- Manufacturing batch certificate
- Recruitment status update
Correct Answer: Signal validation report with recommended regulatory actions or further investigation
Q30. Why must sponsors maintain oversight of CRO pharmacovigilance activities?
- Because sponsors hold ultimate regulatory responsibility and must ensure compliance
- Because CROs cannot be legally contracted
- Because CROs are not qualified to handle any PV tasks
- Because oversight replaces the need for PV agreements
Correct Answer: Because sponsors hold ultimate regulatory responsibility and must ensure compliance
